Global Nanobiosensors in Healthcare Market is expected to register a CAGR of 9.84% from 2019 to 2024.
Nanotechnology in the biosensor is known as nanobiosensor; biosensors are analytical devices used for detection of chemical and biological substances in the human body. Nanobiosensors are the sensors that are made up of nanomaterials and have dimensions between 1 to 100 nanometers. Nanobiosensors are becoming popular in developed countries. The rising prevalence of diabetes in emerging economies, demand for advanced monitoring systems, and raising awareness about advance nanobiosensors are expected to drive the growth of the market. According to the International Diabetes Federation (IDF), it is estimated that the number of diabetic patients in the Middle East and North Africa (MENA) region will grow by 96% from the year 2013 to 2035, i.e., from 34.6 million to 67.9 million. Moreover, rising R&D spending and collaborative strategies adopted by the top players, such as new product launches and collaborations for product development are contributing to the growth of the market.
The rising cost of nanobiosensors and unfavorable reimbursement policies may hamper the growth of the market during the assessment period.
Segmentation
The global nanobiosensors in healthcare market has been segmented on the basis of type, application, end user, and region.
On the basis of type, the market has been classified as optical nanobiosensor, electrochemical nanobiosensor, acoustic nanobiosensor, and others. The electrochemical nanobiosensor segment is expected to hold the largest market share of the nanobiosensors in healthcare market owing to its high sensitivity and real-time detection features. Based on the application, the market has been segmented into diabetes, immunoassay, cancer, pathogenic bacteria, and others. The market, by end user, has been divided into as hospitals and clinics, diagnostic centers, point of care, and others. However, based on end user point of care testing segment holds the largest market share due to low complex infrastructure and training.
Key Players
Some of the prominent key players in the global nanobiosensors in healthcare market are Abbott Point of Care, Inc., F. Hoffman-LA Roche Ltd., Medtronic Inc., Nano-Proprietary, Inc., Lifescan, Inc., Illuminex Corporation, Lifesensors, Inc., ACON Laboratories, Inc., Pharmaco-Kinesis Corporation, Bayer Healthcare AG, Bio-Rad Laboratories, Inc., Biosensors International Pte. Ltd., Sysmex Corporation.
Regional Analysis
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nanobiosensors in healthcare market in the Americas has further been segmented into North America and South America, with the North America market further classified into the US and Canada.
The European nanobiosensors in healthcare market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The nanobiosensors in healthcare market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The nanobiosensors in healthcare market in the Middle East & Africa has been segmented into the Middle East and Africa.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/nanobiosensors-in-healthcare-market-7993
No comments:
Post a Comment